© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.
January 25th 2022
Expert oncologist Aditya Bardia, MD, MPH, provides a broad overview of minimal residual disease testing across a number of tumor types and clinical settings.
Barry Rosen, MD, provides an overview of circulating tumor DNA’s role in early stage breast cancer detection and management.
February 1st 2022
Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.
Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.
February 9th 2022
Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.
A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.
February 16th 2022
Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.
Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.